Se­nior R&D ex­ec Sue Dil­lon jumps ship at J&J, launch­es mys­tery biotech start­up Aro with Cen­tyrins tech

Two for­mer ex­ec­u­tive heavy­weights at John­son & John­son have left the phar­ma gi­ant to launch a rather stealthy start­up called Aro Bio­ther­a­peu­tics – and they are start­ing out with some drug tech they’re al­ready close­ly fa­mil­iar with.

The com­pa­ny’s pres­i­dent and CEO is Sue Dil­lon, an R&D cham­pi­on and the ex-glob­al ther­a­peu­tic area head for im­munol­o­gy in the Janssen Phar­ma­ceu­ti­cals unit of J&J. Her co-founder and CSO is Karyn O’Neil, the for­mer ven­ture leader for Cen­tyrex, an­oth­er J&J unit.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER